CoChat
Sign Up
Cited by 115Substance Abuse Treatment and OutcomesSchizophrenia research and treatmentMental Health Treatment and Access

The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.

Treatment of dual diagnosis disorders

Murthy, Pratima, Chand, Prabhat·2012·Current Opinion in Psychiatry
DOI 10.1097/yco.0b013e328351a3e0
Open this paper in CoChat — free account

Abstract

PURPOSE OF REVIEW: Treatment of dual diagnosis [co-occurrence of a substance use disorder (SUD) in patients with mental illness] poses several challenges for mental health professionals. This article seeks to review the recent advances in dual diagnosis treatment with respect to pharmacotherapy and psychosocial approaches. RECENT FINDINGS: Atypical antipsychotics are commonly used for comorbid schizophrenia and SUD. Whereas there is no difference between risperidone and olanzapine, clozapine appears to have a distinct advantage in reducing psychotic symptoms as well as substance abuse (including smoking). There is emerging evidence that quetiapine is beneficial in dually diagnosed patients, particularly using alcohol, cocaine and amphetamine. A combination of naltrexone and sertraline was found to be effective in patients with depressive disorder and alcohol dependence. Effectiveness of atomoxetine is yet to be established in patients with comorbid adult attention-deficit/hyperactivity disorder with respect to decrease in substance abuse. Integrated intervention is the choice of treatment for patients with dual diagnosis. SUMMARY: In spite of the high association between substance use and psychiatric disorders, there is a surprising paucity of studies related to treatment and outcome. A few well-designed studies have been recently published and more studies of this nature are required in order to address the challenges posed in the treatment of dual disorders.

Overview

Integrity signals

Registry

Crossref · 10.1097/yco.0b013e328351a3e0

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 42 references

Research works printed but not linked: 3

  1. Sattar, 2007, Valproate in the treatment of bipolar disorder and comorbid substance abuse: a 24-week open label trial., Biol Psychiatry, 61, 46S
  2. Erdogan, 2010, Quetiapine in substance use disorders, abuse and dependence possibility: a review in Turkish., Turk Psikiyatri Derg, 21, 167
  3. Hides, 2011, Does the addition of integrated cognitive behaviour therapy and motivational interviewing improve the outcomes of standard care for young people with comorbid depression and substance misuse Med J, Aust, 195, S31

Cited by

Sorted by citations

Items 101–115 of 115

Related

See all

Metadata

Authors
Murthy, P., & Chand, P.
Affiliations
National Institute of Mental Health and Neurosciences (IN)
Corresponding author
Murthy, Pratima
ORCID
Venue
Current Opinion in Psychiatry
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2012-05
Volume
25
Issue
3
Pages
194-200
ISSN
0951-7367 (ISSN-L)
DOI
10.1097/yco.0b013e328351a3e0
OpenAlex
W2067425226
Cited by
115
References
42
Citations by year
2026: 5 · 2025: 4 · 2024: 10 · 2023: 3 · 2022: 7 · 2021: 12 · 2020: 4 · 2019: 8 · 2018: 7 · 2017: 8 · 2016: 11 · 2015: 11 · 2014: 15 · 2013: 10
FWCI
1.44
Type
journal article
Language
en
Open access
closed
Locations
  • Current Opinion in Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
Keywords
dual diagnosis, substance use disorders, psychiatric comorbidity, pharmacotherapy, psychosocial interventions, atypical antipsychotics, clozapine, risperidone, olanzapine, quetiapine, naltrexone, sertraline, atomoxetine, integrated intervention, alcoholism, smoking, cocaine, amphetamine, attention deficit hyperactivity disorder
MeSH terms
Mental Disorders, Drug Therapy, Combination, Humans, Narcotic Antagonists, Psychotherapy, Antipsychotic Agents, Comorbidity, Diagnosis, Dual (Psychiatry), Substance-Related Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review